Previous 10 | Next 10 |
WEST LAFAYETTE, Ind., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and de...
WEST LAFAYETTE, Ind., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and de...
WEST LAFAYETTE, Ind., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and de...
WEST LAFAYETTE, Ind., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and de...
-- Expected to establish a leading global provider of full-spectrum, preclinical and clinical biotherapeutics and biomarker analysis solutions -- -- Expected to enhance scale, broaden customer base and create significant cross-selling opportunities -- WEST LAFAYETTE, Ind.,...
Inotiv, Inc. (NOTV) Q4 2021 Results Conference Call December 16, 2021 04:30 PM ET Company Participants Devin Sullivan - SVP, The Equity Group Bob Leasure - President and CEO Beth Taylor - CFO Conference Call Participants Kyle Bauser - Colliers Securities Matt Hewitt - Craig-Hallum Capital Gro...
Inotiv (NASDAQ:NOTV): FQ4 GAAP EPS of $0.06 beats by $0.19. Revenue of $30.08M (+90.7% Y/Y) in-line. Shares -0.47%. Press Release Gross profit increased 123.0% to $10.3 million, from $4.6 million in Q4 FY 2020, reflecting higher revenue and a 496 basis point expansion in gross margin to 34.3%...
WEST LAFAYETTE, Ind., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”) , a leading contract research organization specializing in nonclinical and analytical drug discovery and d...
Avantor is a fascinating way to play the broader science industry due to its vast portfolio of offerings. Recent performance by Avantor has been appealing, with revenue and cash flows rising while losses turn to profits. AVTR stock is pricey but relative to the growth the company ...
Inotiv (NASDAQ:NOTV) is scheduled to announce FQ4 earnings results on Thursday, December 16th, after market close. The consensus EPS Estimate is -$0.13 (+18.8% Y/Y) and the consensus Revenue Estimate is $30.1M (+90.5% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions an...
News, Short Squeeze, Breakout and More Instantly...
WEST LAFAYETTE, Ind., June 10, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and rela...